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Abstract: With the emergence of immunotherapies for cancer treatment, there is a rising 
clinical need to visualize the tumor microenvironment (TME) non-invasively in detail, which 
could be crucial to predict the efficacy of therapy. Nuclear imaging techniques enable whole-
body imaging but lack the required spatial resolution. Conversely, near-infrared 
immunofluorescence (immuno-NIRF) is able to reveal tumor cells and/or other cell subsets in 
the TME by targeting the expression of a specific membrane receptor with fluorescently 
labeled monoclonal antibodies (mAb). Optical coherence tomography (OCT) provides three-
dimensional morphological imaging of tissues without exogenous contrast agents. The 
combination of the two allows molecular and structural contrast at a resolution of ~15 µm, 
allowing for the specific location of a cell-type target with immuno-NIRF as well as revealing 
the three-dimensional architectural context with OCT. For the first time, combined immuno-
NIRF and OCT of a tumor is demonstrated in situ in a xenograft mouse model of human 
colorectal cancer, targeted by a clinically-safe fluorescent mAb, revealing unprecedented 
details of the TME. A handheld scanner for ex vivo examination and an endoscope designed 
for imaging bronchioles in vivo are presented. This technique promises to complement 
nuclear imaging for diagnosing cancer invasiveness, precisely determining tumor margins, 
and studying the biodistribution of newly developed antibodies in high detail. 
© 2018 Optical Society of America under the terms of the OSA Open Access Publishing Agreement 
1. Introduction 
Over the past two decades, immunotherapy has attracted interest as a potentially 
revolutionary technique in cancer treatment. There are several immunotherapy strategies, for 
example, using monoclonal antibodies (mAbs) to stimulate the body’s immune response to 
attack the cancerous cells [1], inhibiting tumor growth by blocking receptors or growth 
factors with mAbs [2], or even specifically deliver cytotoxic drugs to cancer cells with 
antibody-drug conjugates [3,4]. To predict treatment outcome and/or monitor treatment 
success, imaging techniques showing the biodistribution of these mAbs in vivo are needed. In 
particular, assessing the degree of heterogeneity of the tumor microenvironment (TME) and 
the interaction between immune cells and tumor cells have been suggested as a prognostic 
marker [5]. Non-invasively diagnosing the infiltration of a tumor into the mucosa and 
submucosa could be achieved by molecular imaging using mAbs, therefore avoiding taking 
biopsies. Moreover, identification of the tumor margin and real-time tumor specific imaging 
would help in image-guided surgery. 
One approach is radioactively labeling the antibody and following its distribution with 
positron emission tomography (PET) or single-photon emission computed tomography 
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(SPECT). The combination with morphological imaging provided by computed tomography 
(CT) or magnetic resonance imaging (MRI) is particularly powerful, because it allows the 
identification of the anatomical location targeted by a mAb and provides the architectural 
context at a whole body level. The limited spatial resolution of around 5 mm of PET and 
SPECT, however, does not permit studying the TME in sufficient detail and to accurately 
define tumor margins, tumor invasiveness, and the cellular composition of tumors. Moreover, 
PET and SPECT have a scan time of about 1 hour, prohibiting real time imaging for image-
aided surgery. Finally, only one marker at a time can be tracked with nuclear imaging. These 
limitations can be overcome with optical techniques, such as fluorescence imaging, which 
typically have a resolution in the order of microns, allowing imaging at the (sub-)cellular 
level, have a typical scan time of a few seconds to minutes and allow imaging multiple mAbs 
by using spectrally separated fluorophores. Although the penetration depth of light in tissue is 
limited, most tumors originate at the epithelial layers of organs, and are therefore in the large 
majority of cases accessible through endoscopic imaging. Labeling mAbs with fluorescent 
molecules for targeted imaging has been demonstrated in the early 90’s [6–8] and has gained 
new interest for in vivo imaging with the development of conjugation-suitable near infrared 
fluorophores [9–12]. 
Tumors in the lumen walls of organs such as colon, esophagus, and lungs, are accessible 
by purposely-designed endoscopes. Technical advancements facilitated the progress towards 
increasingly compact endoscopic optical coherence tomography (OCT)-fluorescence systems 
[13–22], in particular the development of highly efficient double-clad fiber couplers [23,24]. 
To date, only two studies have combined OCT and immuno-fluorescence in an endoscopic 
platform, but in both cases the experiments were performed on excised tissue only. Liang et 
al. [25] stained aorta tissue sections from rabbits with atherosclerosis with Annexin-Cy5.5 
(excitation peak 675 nm), which allowed identification of necrotic and inflamed regions. 
Scolaro et al. [26] imaged excised mouse liver incubated with an EpCAM antibody 
conjugated to Alexa Fluor 488 (490 nm excitation peak), allowing identification of epithelial 
cells specifically. Several drawbacks in using visible-region wavelengths were identified, 
including limited penetration depth, conspicuous tissue autofluorescence [27], and reduced 
permitted illumination fluence. Most importantly, none of these dyes is in the process of 
being translated into clinical use [28]. Compared to fluorophores in the visible range, 
excitation/emission peaks of IRDye800CW in the near-infrared region (780/805 nm) ensure 
increased penetration depth due to reduced scattering, and higher signal-to-background ratio 
due to the low autofluorescence of practically all tissues in this spectral region [27]. 
In this paper, we present in situ near-infrared immuno-fluorescence (immuno-NIRF) 
combined with Optical Coherence Tomography (OCT) using a mouse model bearing human 
colon cancer. We also present a galvo-based scanner for tumor ex vivo examination and an 
endoscope designed to reach the human lung periphery in vivo. With its ~15 µm resolution, 
immuno-NIRF has the potential to provide microscopic molecular contrast of the TME. OCT 
provides three-dimensional structure at ~15 µm spatial resolution without additional 
exogenous contrast agents [29]. Immuno-NIRF and OCT complement each other by 
visualizing molecular contrast within the surrounding tissue architectural context, in analogy 
to PET-CT or PET-MRI. The mAb labetuzumab, labeled with a near-infrared fluorescent 
molecule and the PET isotope zirconium-89, provides molecular whole body and local 
imaging by targeting the carcinoembryonic antigen (CEA), which is abundantly expressed by 
colorectal cancer cells. The compound was administered intravenously in live mice three days 
before imaging, for optimal targeting of the cancer cells. We used the near-infrared cyanine 
fluorophore IRDye800CW because of its low toxicity, good brightness, and, most 
importantly, the possibility to conjugate it inertly to antibodies [30]. Recently, IRDye800CW 
has been the object of several clinical trials focused on intraoperative imaging [31–36], 
showing its potential for clinical applications. 
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2. Materials and methods 
We developed and assembled a custom-built optical setup and endoscopic scanner designed 
for in vivo imaging in clinical and preclinical settings. In a virtually all-fiber implementation 
the system efficiently combined and separated OCT and NIRF signals using a double-clad 
fiber coupler (Fig. 1). Similar designs have shown the combination of OCT with fluorescence 
imaging [14–21], laser tissue coagulation [37], near-infrared spectroscopy [38], and 
hyperspectral imaging [39]. The design is versatile in the sense that it can be adapted to detect 
spectrally separated fluorophores simultaneously, retrieve the tissue autofluorescence, or 
implement other techniques such as white light spectroscopy. 
2.1. Optical setup 
Two scanning interfaces were developed, a galvo-based “handheld” scanner and an 
endoscope designed for imaging lung airways. The use of optical fibers ensures stable optical 
alignment and easy switching between the handheld scanner and the endoscope. The OCT 
setup is based on a swept source laser (Axsun Inc., Billerica MA, USA) centered at 1310 nm 
with a 90 nm bandwidth and 50 kHz sweep rate. A single wavelength of the sweep reflected 
from a fiber Bragg grating (FBG) functions as a main trigger for the whole system, 
synchronizing the OCT and NIRF data acquisition to the scanners. A 90/10 beam splitter 
directs the light into two arms of a Mach-Zehnder interferometer which features a circulator 
in the sample arm for increased sensitivity, and a spectrally-flat polarization diversity 
detection unit (PDDM1310, Finisar Corp., Sunnyvale, CA, USA) for optimal balanced 
detection. The signals from the balanced detectors (PDB430AC, Thorlabs Inc., Newton, NJ, 
USA) are digitized by a high-speed acquisition card (ATS9350, Alazar Tech. Inc., Pointe-
Claire, Canada). The OCT system is combined with the excitation source for fluorescence via 
an SMF-28 fiber-based wavelength division multiplexer (WD6513A, Thorlabs Inc., Newton, 
NJ, USA), to maximize 1310 nm throughput, at the cost of slight multimodal operation at the 
NIRF excitation wavelength. In the NIRF system, light from a single mode diode laser 
(780CW Thorlabs Inc., NJ, USA) passes through a cleanup filter (FF01-769/41-25, Semrock 
Inc. Rochester, NY, USA) before being combined with the OCT light. The two signals are 
incorporated into the single mode core of a double clad coupler (DC1300LEFA Castor 
Optics, Thorlabs Inc., Newton, NJ, USA). Single-mode illumination is necessary for OCT, 
and it simultaneously provides a focused excitation beam for better imaging resolution of the 
fluorescence. The light is delivered to the sample via one of the two scanning devices, either 
the DCF based endoscope or the ‘handheld’ scanner. The light scattered back from the sample 
is collected by both the single mode core and the inner cladding of the DCF fiber. Being an 
interferometric technique, OCT requires single spatial mode detection and the DCF coupler 
ensures that the single-mode core light is not mixed with the cladding light and efficiently 
transmitted (insertion loss <0.5 dB) between the input and output ports. On the other hand, 
NIRF is an incoherent technique, therefore it benefits from increased collection efficiency by 
the large 105 µm diameter and 0.2 NA of the first cladding. The DCF coupler extracts about 
65% of the cladding light through the 200 µm multimode fiber port. After removing 
undesired radiation (BLP830RE, cut-on wavelength 832.5 nm, Semrock Inc. Rochester, NY, 
USA and FESH0900, cut-off wavelength 895.5 nm, Thorlabs Inc., Newton, NJ, USA) the 
light is coupled into another 200 µm multimode fiber with a light-tight jacket to reduce 
collection of the ambient light, finally reaching a single-photon avalanche photodetector 
(SPAD) set in photon counting mode. The SPAD (SPCM-NIR, Excelitas Technologies 
GmbH, Wiesbaden, Germany) has a dark count rate of 250 count-per-second and a maximum 
count-rate of 40 × 106 cps, with a detection efficiency of 68% at 800 nm. The output of the 
SPAD is a series of TTL pulses that are recorded by an acquisition module (PCIe 6259, 
National Instruments, Austin, TX, USA) and shown in real time together with the OCT B-
scans (cross-sections). 
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2.5. Characterization of NIRF detection limit and SNR 
To demonstrate that avoiding the photoluminescence emitted by the silica fibers is crucial for 
improving the signal-to-noise ratio, we measured solutions of IRDye800CW of increasing 
concentration with two different filter settings. Based on the emission spectrum of 
IRDye800CW (see Fig. 3(a), a long pass filter with cut-on wavelength at 805 nm (BLP785R, 
Semrock Inc. Rochester, NY, USA) integrates most of the IRDye800CW emission, while 
collecting also a significant amount of photoluminescence. In comparison, a long pass filter 
with a cut-on wavelength of 832.5 nm (BLP830RE, Semrock Inc. Rochester, NY, USA) 
integrates about one sixth of the emitted fluorescence, but allows significantly less 
photoluminescence to be detected. In both cases, a shortpass filter with 895.5 nm cut-off 
wavelength was used to effectively reject the OCT light. We compared these filter settings by 
imaging serum solutions of IRDye800CW to closely mimic the spectral characteristic of the 
dye in a real situation. For the galvo-based scanner, we placed the focal spot of the objective 
about 0.5 mm below the surface of the solution, and scanned the mirrors over an area of 1x1 
mm2. We varied the concentration between 0.3 nM and 30 nM, with an excitation power of 
575 ± 5 µW. The endoscope was inserted in a sealed glass capillary (1.5 mm internal diameter 
(ID), 1.9 mm outer diameter (OD)) to avoid contamination of the endoscope and the motor 
was actuated at the imaging scan rate of 52 rotations/sec. The concentration range was 10 nM 
to 1 µM, with an excitation power of 175 µW for the narrow band filter combination (832.5 – 
895.5nm), and 62 µW for the broadband filter combination (805 - 895.5nm). The excitation 
power for the broadband filter was reduced to avoid saturation of the detector. For both 
scanners, 100,000 consecutive measurements with an individual integration time of 20 µs 
were taken. The SNR in dB was defined as 
 1010 log






where S is the average measured intensity in counts-per-second from the fluorescent solution, 
B is the average measured intensity of a blank solution at the same power setting and Bσ  its 
standard deviation. 
2.6. NIRF imaging resolution 
Even though fluorescence is detected by the first cladding of the DCF, the NIRF optical 
resolution is largely determined by the point-spread-function (PSF) of the beam originating 
from the single mode core of the DCF. Indeed, only the molecules present in the volume 
illuminated by the single-mode core will fluoresce. Because of the different geometry of light 
illumination and collection in the two scanners, the PSF of the NIRF signal was determined 
with two different phantoms. For the endoscope, the PSF was measured by scanning a sparse 
suspension of fluorescent beads (Ex/Em wavelength 715/755 nm, diameter 0.1 µm, F8799, 
Thermo Fischer, Waltham, MA, USA) in a viscous solution (polyethylene glycol-glycerol-
water with ratio 50:10:40). A sealed transparent capillary glass (ID 1.5 mm, OD 1.9 mm) was 
inserted in the suspension to function as a guide for the endoscope, preventing it to come in 
direct contact with the beads. The motor of the endoscope was actuated at normal speed (52 
fps) and the endoscope was pulled back through the capillary at a speed of 0.2 mm/s to 
guarantee even sampling density in the two dimensions. The PSF of several isolated beads in 
the NIRF image was measured by fitting a two-dimensional Gaussian distribution, yielding an 
average PSF of 15 µm. For the galvo-based scanner, the resolution of the NIRF channel was 
measured by imaging a fluorescent USAF target (#57-855, Edmund Optics Ltd. UK, York, 
UK). The smallest feature that can be resolved was in element 1 of group 5, corresponding to 
a full-width-at-half-maximum of 22.3 µm. The PSF of the beam in the focus generated by the 
objective is specified to be 18 µm, but the core of the DCF does not guarantee single-mode 
operation for the NIRF excitation wavelength preventing reaching the theoretical PSF. 
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2.7. Animal model 
Three mice (age, 8-10 weeks; body weight, 22-28 gram; Envigo, Horst, The Netherlands) 
were injected intraperitoneally (i.p.) in the pelvis with human colon cancer cells. The mice 
were kept in sterile surroundings at 24°C and 60% humidity with standardized light/dark 
cycle and access to food and water ad libitum. 
Cell line: LS174T colon cancer cells (ATCC CL-188) were cultured in Dulbecco’s 
modified Eagle's medium (DMEM Lonza BE12-709F, supplemented with 1% L-glutamine 
(Lonza BE17-605E) and 10% fetal bovine serum (FBS; Gibco 10270) at 37 °C, 5% CO2. Two 
weeks before imaging, the mice were anaesthetized with inhalation anaesthetics (isoflurane 
2–2.5% and oxygen 0.45 volume %) after which 1x106 cells in 300 µL culture medium 
without FBS were i.p. injected. After imaging with PET-CT and with a wide-field 
fluorescence imager, the mice were sacrificed and tumor tissue was rapidly excised for further 
imaging. The freshly excised tumors were not fixed. 
Animal experiments were performed according to the criteria and guidelines of European 
Community Council Directive 2010/63/EU for laboratory animal care and the Dutch Law on 
animal experimentation. The local committee of the Amsterdam University Medical Center 
approved the animal experimental protocol. 
2.8. Tracer synthesis and PET-CT imaging 
Labetuzumab is a complementarity-determining region (CDR)-grafted (humanized) CEA-
specific (CEACAM5) immunoglobulin G1 subclass monoclonal antibody that was kindly 
provided by Dr. D.M. Goldenberg, Immunomedics, Inc. (Morris Plains, NJ) [43]. The 
compound [89Zr]Zr-labetuzumab-IRDye800CW was synthesized as described previously 
[30], with a radiochemical purity > 95%. Mice were anaesthetized using inhalation 
anesthetics (isoflurane 2–2.5% and oxygen 0.45 volume %) and injected retro-orbital with 
100 µg of compound (dose 1 MBq, injection volume 100 µL). Three days after injection, the 
mice were placed on the integrated heating bed of a PET-CT (Mediso nanoPET-CT, 
Budapest, Hungary) while monitoring respiratory function. A computed tomography (CT) 
scan was performed for 6 min, followed by a PET scan of 60 min. PET data were normalized, 
and corrected for scatter, randomization, attenuation, decay and dead time. Thereafter, mice 
were placed in a wide-field NIR fluorescence imager (In-Vivo Xtreme Imager, Bruker, 
Leiderdorp, The Netherlands) with excitation and emission filters of 760 nm and 830 nm, 
respectively for NIR fluorescence imaging for 5 sec. After imaging, the mice were sacrificed 
and all visible tumor lesions were taken out for ex vivo wide-field NIR fluorescence imaging. 
2.9. Optical imaging of human colorectal tumors in a xenograft mouse model 
After imaging the mice in the PET-CT scanner and the wide-field NIR fluorescence imager, 
they were sacrificed. Thereafter, a small incision in the skin was made to insert the endoscope 
for imaging. In this mouse xenograft model, the tumor masses spread across the peritoneum 
and were not growing inside the lumen of a specific organ. While scanning with the 
endoscope, the NIRF signal served as a reliable and fast guide, exhibiting a good signal-to-
background ratio when a tumor was in its proximity. Once a suspicious location was 
identified, the endoscope was pulled back at a constant speed of 0.2 mm/s with a linear 
translation stage (A-LSQ150B, Zaber Technologies Inc. Vancouver, BC, Canada) and about 
one thousand B-scans at a rate of 52 fps (960 A-lines per B-scan) were acquired. The 
acquired NIRF data were shown in real time in an en face (coronal) image of the scanned 
area, giving immediate feedback. Moreover, OCT B-scans were displayed continuously at 
video rate. After the acquisition of several volumes, skin and peritoneum were cut open and 
the galvo scanner head was positioned above the belly. The fast axis galvo mirror was run 
continuously providing video rate 1D NIRF and OCT B-scans, which are particularly useful 
to position the focus at an optimal depth in the tissue. Also in this instance, the NIRF signal 
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was used as a navigation tool, thanks to its high specificity to tumor locations. Once an 
interesting location was identified, full OCT C-scan (1000 B-scans of 1000 A-lines) and 2D 
NIRF images (1000x1000 pixels) were acquired simultaneously. A live composition of a 
NIRF en face image was displayed to give immediate feedback on the image quality. Videos 
of the volumetric scans for both endoscope and galvo scanner are available as supplementary 
materials. In this report, the images are shown in inverted order with respect to the 
chronological acquisition order, first the galvo scanner images of an excised tumor, then in 
situ galvo scanner images, finally an endoscopic scan. 
2.10. OCT-NIRF data acquisition and image reconstruction 
The measurements were performed in a regular room but with the ceiling lights off and 
blinded windows. First, a background measurement for the NIRF and a reference arm-only 
measurement for the OCT were taken. The incident power on the sample was measured 
before every scan. For the endoscope the incident power was 0.67 mW for the 780 nm NIRF 
excitation and 10 mW for the 1310 nm OCT. For the galvo-based scanner, the incident power 
of the NIRF excitation band was 1.0 mW and 9 mW for the OCT, due to the sub-optimal 
antireflection coating of the objective we used. The raw OCT spectra were acquired equally 
sampled in k-space and Fourier transformed to create A-lines as described previously [44], 
with the B-scans eventually displayed with a 55 dB dynamic range. We chose to show the 
images in inverted grayscale because it improves the visualization of lower-SNR details. The 
fluorescence raw data were converted into counts-per-second and the factory-provided 
correction curve for the non-linear response of the SPAD was applied. The data were 
displayed in grayscale en face images, with the lower bound of the grayscale being the 
background and the upper bound 0.8 times the highest count rate of the image, to maximize 
the dynamic range. Finally, we displayed the cross-sectional OCT B-scans with the co-
registered one-dimensional NIRF along the scanning axis to facilitate the identification of the 
tumor lesions in the OCT images. 
2.11. Automatic OCT B-scan segmentation 
A novel method based on shortest path search algorithm [45] was developed, using intensity 
OCT B-scans in rectangular format without advanced denoising procedures. After computing 
an integral image and blurring it with a 12-by-12 average Gaussian filter, a vertical gradient 







Our algorithm was initialized automatically by adding two extra nodes with zero 
cost before the first and after the last A-line of each B-scan, acting as source and sink of the 
graph. Finally, the shortest path search to find the minimum cost path among its eight 
neighboring pixels was applied and the air-to-tissue boundary was found. To precisely find 
the outer surface of the endoscope sheath, two iterations were necessary. In some situations 
the tumor protruded considerably along the axial dimension with respect to the rest of the 
tissue, causing the segmentation algorithm to fail. Therefore, each B-scan was divided into 
subsections representing either tumor or other tissues, using the tissue-to-tumor boundary 
determined by segmenting the en face NIRF image with the Chen-Vese method [46]. Each 
subsection was segmented separately, and then merged to cover the whole B-scan. 
3. Results 
3.1. Characterization of photoluminescence in DCF silica fibers 
The fluorescence excitation light propagating in a glass fiber generates photoluminescence, 
increasing the background and reducing the SNR of NIRF. Figure 3(a) shows the 
photoluminescence generated by 780 nm light propagating through a passive silica DCF 
(Nufern SM-9/105/125-20A). From the spectrum shape, and the fact that it shifts with the 
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therefore a non-uniform distribution of antibodies is expected, even at high doses. 
Importantly, NIRF imaging also allows a direct identification of the tumor mass in the OCT 
cross sections, for example, in Fig. 6(c-e). OCT imaging provides the tissue architectural 
context that helps in further distinguishing the various tissues, and possibly gives information 
on the tumor infiltration in the mucosa and submucosa. 
We envision the introduction of immuno-NIRF-OCT imaging as an addition to the current 
nuclear/fluorescence imaging and a firm step to come to “non-invasive in vivo 
immunohistochemistry”, allowing to study tumor responses to newly developed 
immunotherapeutic antibodies at a scale that is not otherwise accessible. It would also enable 
longitudinal studies within the same patient since endoscopic immuno-NIRF-OCT has the 
potential to reduce the necessity of biopsy sampling. This could be very beneficial to unveil 
the mechanisms at the base of resistance to immunotherapy for particular subgroups of 
patients. Since immuno-NIRF provides excellent contrast, it could aid in the diagnosis, 
provided that a suitable mAb target can be found. Moreover, it would be interesting to attach 
spectrally separated fluorophores to various mAb and/or ligands, opening the possibility to 
visualize antibody-ligand and cell-cell interactions, not achievable with nuclear imaging. The 
NIRF-OCT endoscope was designed to be inserted thorough the working channel of 
commercial bronchoscopes and deployed to the site of interest in the central or peripheral 
airways, as an addition to the standard procedure. Due to its small size, another possible 
application of the endoscope is bile duct imaging. Importantly, the detection sensitivity of our 
setup suggests that antibody concentrations anticipated in a person injected with a micro-dose 
of immuno-imaging agents can be detected, which is important to facilitate the path towards 
use in humans. For instance, by quantifying the uptake of immuno-PET tracers in tumors, it is 
possible to estimate the local concentration of the injected antibody in a tumor, in humans 
[51]. By injecting a micro-dose of mAbs (about 4.5 mg in an adult human, the molecular 
weight of a typical fluorescently labeled mAb is ~151·103 g/mol), a typical accumulation of 
0.020% injected dose/gram can be expected in a tumor, translating to an average mAb-PET 
tracer concentration of about 6 nM in a tumor, with the sensitivity of our endoscope close to 
this target while the one of the galvo-based scanner well within. As for more immediate 
clinical applications, this platform would also allow to delineate the tumor margins with high 
accuracy and to laser-mark its boundaries. The added value of the structural imaging provided 
by OCT in this context is multifold. For example, one could assess the stage of 
progression/regression of the disease by visualizing the degree of penetration of the tumor 
into the mucosa and submucosa. Importantly, OCT could provide a means to determine the 
optical properties of the tissue, helping to quantify the absolute intensity of the NIRF signal 
and in turn, the antibody uptake. Finally, OCT is able to resolve the microvasculature network 
in three dimensions, without exogenous contrast agents, providing valuable information on 
the tumor activity [52]. 
As for technical considerations on the quality of the images, the immuno-NIRF images 
generated with the galvo scanner are superior to the endoscope ones. One reason is the 
background noise generated in the fiber is increased for the endoscope, since the length of 
DCF is about 250 cm for the endoscope, compared to about 30 cm for the galvo-based 
scanner. Also, the insertion and transmission losses of the NIRF excitation and collection are 
higher in the endoscope by about a factor of two. The endoscope includes miniaturized 
optical elements such as the GRIN lens and an aluminum coated microprism, which has a 
reflectivity of only 75% at 800 nm. From our simulations, it appears that the collection cone 
of the cladding is slightly overfilling the mirror, giving a sub-optimal collection efficiency 
throughout the rotation. Finally, the chromatic aberration induced by the GRIN lens causes 
the NIRF beam to focus about 175 µm more superficially than the OCT, leading to 
suboptimal excitation fluence deeper in the tissue. The DCF fiber affects the galvo scanner 
(30 cm DCF) and endoscope (250 cm DCF) OCT images. Coupling of the backscattered OCT 
light transported through the DCF cladding into the single mode core at the junction between 
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the DCF coupler and the SMF exhibits different behavior because of the different length of 
DCF involved. In the galvo scanner case, this cross talk creates a semi-coherent image that 
appears as an echo above the confocal OCT images, because of the lower refractive index of 
the cladding. For the endoscope, the cross talk prevents shot-noise-limited detection because 
of increased radiation reaching the photodetectors, but it does not create an echo because it 
falls out of the coherence length of the laser. 
In conclusion, immuno-NIRF-OCT enables minimally invasive imaging of tumors with 
high resolution, complementing nuclear imaging by providing high definition molecular and 
structural images of the TME. 
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